The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer

Cancer Genetics and Cytogenetics

Volumn 187, Issue 1, 2008, Pages 28-33

  Celhar, Teja ^a   Gersak, Ksenija ^b   Ovcak, Zdenka ^a   Sedmak, Boris ^b   Mlinaric Rascan, Irena ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING);

ADULT; ARTICLE; CANCER GROWTH; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOMIC INSTABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SLOVENIA;

ADOLESCENT; ADULT; ALLELES; BASE SEQUENCE; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; GENITAL NEOPLASMS, MALE; GENOTYPE; HUMANS; MALE; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECURRENCE; REFERENCE VALUES; RISK FACTORS; SEMINAL VESICLES; SLOVENIA;

EID: 55049102098     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.08.003     Document Type: Article

References (27)

1. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.L., and Thun M.J. Global Cancer Facts & Figures 2007 (2007), American Cancer Society, Atlanta, GA
2. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer Incidence. Mortality and Prevalence Worldwide (2004), IARCPress, IARC CancerBase No. 5, Version 2.0. Lyon
3. Grönberg H. Prostate cancer epidemiology. Lancet 361 (2003) 859-864
4. Ntais C., Polycarpou A., and Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 149 (2003) 469-477
5. Gsur A., Feik E., and Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 21 (2004) 414-423
6. Payne A.H., and Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25 (2004) 947-970
7. Gharani N., Waterworth D.M., Batty S., White D., Gilling-Smith C., Conway G.S., McCarthy M., Franks S., and Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 6 (1997) 397-402
8. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., Strauss III J.F., Spielman R.S., and Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96 (1999) 8573-8578
9. Diamanti-Kandarakis E., Bartzis M.I., Bergiele A.T., Tsianateli T.C., and Kouli C.R. Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 73 (2000) 735-741
10. San Millán J.L., Sancho J., Calvo R.M., and Escobar-Morreale H.F. Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 75 (2001) 797-802
11. Daneshmand S., Weitsman S.R., Navab A., Jakimiuk A.J., and Magoffin D.A. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17-20) lyase promoters. Fertil Steril 77 (2002) 274-280
12. Gaasenbeek M., Powell B.L., Sovio U., Haddad L., Gharani N., Bennett A., Groves C.J., Rush K., Goh M.J., Conway G.S., Ruokonen A., Martikainen H., Pouta A., Taponen S., Hartikainen A.L., Halford S., Järvelin M.R., Franks S., and McCarthy M.I. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 89 (2004) 2408-2413
13. Wang Y., Wu X., Cao Y., Yi L., and Chen J. A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil Steril 86 (2006) 223-226
14. Kumazawa T., Tsuchiya N., Wang L., Sato K., Kamoto T., Ogawa O., Nakamura A., Kato T., and Habuchi T. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer 110 (2004) 140-144
15. Douglas J.A., Zuhlke K.A., Beebe-Dimmer J., Levin A.M., Gruber S.B., Wood D.P., and Cooney K.A. Identifying susceptibility genes for prostate cancer-a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 14 (2005) 2035-2039
16. Cicek M.S., Liu X., Casey G., and Witte J.S. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14 (2005) 2173-2177
17. Zheng W., Gao Y.T., Shu X.O., Wen W., Cai Q., Dai Q., and Smith J.R. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 13 (2004) 709-714
18. Ferk P., Gersak K., and Teran N. No association between the microsatellite polymorphism (TTTTA)n in the promoter region of the CYP11A gene and ovarian hyperstimulation syndrome. J Assist Reprod Genet 23 (2006) 29-32
19. Piras I., Falchi A., Moral P., Melis A., Giovannoni L., Paoli G., Calò C., Vona G., and Varesi L. Frequencies of promoter pentanucleotide (TTTTA)n of CYP11A1 gene in European and North African populations. Genet Test 12 (2008) 93-96
20. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
21. International Union Against Cancer (UICC). TNM classification of malignant tumors. 6th Ed. (2002), Wiley & Sons, New York
22. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273-279
23. Aus G., Abbou C.C., Bolla M., Heidenreich A., Schmid H.P., van Poppel H., Wolff J., and Zattoni F. for the European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
24. Miller S., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
25. Scattoni V., Montorsi F., Picchio M., Roscigno M., Salonia A., Rigatti P., and Fazio F. Diagnosis of local recurrence after radical prostatectomy. BJU Int 93 (2004) 680-688
26. Downs T.M., Kane C.J., Grossfeld G.D., Meng M.V., and Carroll P.R. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev 21 (2002) 29-44
27. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., and Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523